Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CYTK 
Cytokinetics Inc (CYTK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: CYTK (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
21 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $74.41
1 Year Target Price $74.41
| 9 | Strong Buy |
| 9 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 38.74% | Avg. Invested days 21 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.12B USD | Price to earnings Ratio - | 1Y Target Price 74.41 |
Price to earnings Ratio - | 1Y Target Price 74.41 | ||
Volume (30-day avg) 21 | Beta 0.62 | 52 Weeks Range 29.31 - 59.39 | Updated Date 09/15/2025 |
52 Weeks Range 29.31 - 59.39 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.12 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -167% |
Management Effectiveness
Return on Assets (TTM) -24.87% | Return on Equity (TTM) -572.15% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 6117993386 | Price to Sales(TTM) 71.36 |
Enterprise Value 6117993386 | Price to Sales(TTM) 71.36 | ||
Enterprise Value to Revenue 71.36 | Enterprise Value to EBITDA -15.82 | Shares Outstanding 119657000 | Shares Floating 119101947 |
Shares Outstanding 119657000 | Shares Floating 119101947 | ||
Percent Insiders 0.69 | Percent Institutions 117.94 |
Upturn AI SWOT
Cytokinetics Inc
Company Overview
History and Background
Cytokinetics, Inc. was founded in 1998 and is a biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.
Core Business Areas
- Muscle Biology: Cytokinetics focuses on leveraging its expertise in muscle biology to develop novel treatments for diseases involving muscle dysfunction.
- Drug Discovery and Development: The company discovers and develops small molecule therapeutics designed to impact muscle function.
- Commercialization: Cytokinetics seeks to commercialize its developed therapies, either independently or through partnerships.
Leadership and Structure
The leadership team includes the CEO, CFO, CSO, and other key executives responsible for various aspects of the business. Cytokinetics operates with a functional organizational structure, with departments focused on research and development, clinical operations, commercialization, and corporate functions.
Top Products and Market Share
Key Offerings
- Omecamtiv Mecarbil (cardiac myosin activator): Omecamtiv mecarbil is a selective cardiac myosin activator (SCMA). Marketed as Aficamten. Focus for heart failure with reduced ejection fraction (HFrEF). The product is commercialized with Amgen. Competitors include Novartis' Entresto (sacubitril/valsartan) and generic therapies for heart failure.
- Redomyosin (skeletal muscle troponin activator): Redomyosin is a fast skeletal muscle troponin activator (FSTA). The product focuses on diseases like Spinal Muscular Atrophy (SMA) and Amyotrophic Lateral Sclerosis (ALS). Competing agents for Spinal Muscular Atrophy (SMA) include products from Biogen, Novartis, and Roche
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, regulatory hurdles, and intense competition. Companies focus on innovative therapies to address unmet medical needs.
Positioning
Cytokinetics is positioned as a leader in muscle biology, focusing on developing innovative therapies that target muscle function. Their competitive advantage lies in their expertise and innovative approach to this specific therapeutic area.
Total Addressable Market (TAM)
The total addressable market for therapies targeting heart failure and neuromuscular disorders is substantial, potentially reaching billions of dollars. Cytokinetics is positioned to capture a significant portion of this market with its promising pipeline of muscle-targeted therapies.
Upturn SWOT Analysis
Strengths
- Specialized expertise in muscle biology
- Innovative pipeline of muscle-targeted therapies
- Strategic partnerships with major pharmaceutical companies
- Strong intellectual property portfolio
Weaknesses
- Reliance on clinical trial success
- High R&D expenses
- Dependence on partnership revenues
- Relatively small commercial infrastructure
Opportunities
- Expanding therapeutic applications for muscle activators and inhibitors
- Potential for accelerated regulatory pathways
- Growing prevalence of heart failure and neuromuscular disorders
- Strategic acquisitions of complementary technologies
Threats
- Clinical trial failures
- Regulatory delays or rejections
- Competition from established pharmaceutical companies
- Generic erosion of key products
Competitors and Market Share
Key Competitors
- NVS
- BMY
- PFE
- GILD
Competitive Landscape
Cytokinetics faces competition from established pharmaceutical companies in the cardiovascular and neuromuscular disease space. While smaller than the competitors, Cytokinetics has an advantage through its specialized focus on muscle biology.
Growth Trajectory and Initiatives
Historical Growth: Cytokinetics' historical growth has been driven by advancements in its clinical pipeline and strategic partnerships.
Future Projections: Analyst projections suggest continued revenue growth driven by successful commercialization of its products and advancements in its clinical programs.
Recent Initiatives: Recent initiatives include the advancement of omecamtiv mecarbil in heart failure and the development of new muscle-targeted therapies.
Summary
Cytokinetics is a biopharmaceutical company with a strong focus on muscle biology. The success of Omecamtiv Mecarbil is pivotal for its financial health. Clinical trial outcomes and regulatory approvals are key factors influencing its growth trajectory. Competition from larger pharmaceutical companies poses a continuous challenge. Continued advancements in the pipeline and strategic partnerships are essential for Cytokinetics to achieve its growth objectives.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Industry publications
- Company website
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data and market conditions are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cytokinetics Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2004-04-29 | CEO, President & Director Mr. Robert I. Blum | ||
Sector Healthcare | Industry Biotechnology | Full time employees 498 | Website https://www.cytokinetics.com |
Full time employees 498 | Website https://www.cytokinetics.com | ||
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy. It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.